1 / 11

Welcome and Introduction to the Meeting

Welcome and Introduction to the Meeting. Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003. 2003 Accomplishments Office of Pharmaceutical Science. PAT – Process Analytical Technology Research – Rapid Response: ketamine, KI, doxycycline Pharmacogenomics

chloe-levine
Download Presentation

Welcome and Introduction to the Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome and Introduction to the Meeting Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003

  2. 2003 Accomplishments Office of Pharmaceutical Science • PAT – Process Analytical Technology • Research – Rapid Response: ketamine, KI, doxycycline • Pharmacogenomics • ONDC – Acting Director, Dr. Moheb Nasr • New Office of Biotechnology Products – Acting Director, Dr. Yuan-Yuan Chiu State of CDER 2003

  3. State of CDER 2003 Office of Generic Drugs

  4. State of CDER 2003 Office of Generic Drugs

  5. State of CDER 2003

  6. Commissioner’s Innovation Initiative • Response to falling NME application rates observed world-wide (not unique to FDA) • Overall goal: help streamline/facilitate drug development (NOT shorten review times) • Root cause analysis – multiple cycles • Additional guidances – e.g. pharmacogenomics • Quality systems principles in review process State of CDER 2003

  7. FDA’s Product Quality for the 21st Century Initiative • Two year effort, half way through • Major accomplishments: • Pharmaceutical Inspectorate in field • Final Guidance on Part 11 • PAT draft guidance • ’04 Plans • Finish what is started • Work on internal quality system • ICH and other international harmonization State of CDER 2003

  8. Wrap-Up • 2003 : Record of accomplishments and strengthening of CDER • 2004 brings: • Administrative uncertainties • Scientific challenges • Expectations of continued high performance AND improvements State of CDER 2003

  9. Pharmaceutical cGMP Initiative: Progress as of September ‘03 • Part 11, Electronic Records, Electronic Signatures - Scope and Application (final guidance) • Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP (draft guidance) • Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practices (draft guidance) • Comparability Protocols - Protein Drug Products and Biological Products, Chemistry, Manufacturing, and Controls Information (draft guidance) • PAT - A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance (draft guidance)

  10. Pharmaceutical cGMP Initiative: Progress as of September ‘03 • Cooperative Research and Development Agreement (CRADA) with Pfizer, Inc. • Collaboration with the McDonough School of Business at Georgetown University, Washington, DC, and the Olin School of Business at the Washington University, St. Louis. • Collaboration with the National Science Foundation's Center for Pharmaceutical Processing Research

  11. This Meeting • Subcommittee reports • Draft PAT Guidance report • PTIT proposal for DCU • Risk Based CMC Review • Nomenclature challenges • Generic research program

More Related